

IDEC 131: adverse reactions

Various toxicities

In patients with relapsing-remitting multiple sclerosis

Study Details

Purpose

This study investigated the tolerability of IDEC 131 [α CD154] in patients with relapsing-remitting multiple sclerosis.

Details

Design: sequential
Control: baseline comparison, drug dosage comparison
Phase: Phase I
Concomitant Medication: None

Subjects

Type	No.	Sex	Age
patients	12		not stated

Treatments

IDEC 131 (1 mg/kg)

Drug/Treatment	Dose	Route	Frequency	Duration
IDEC 131	1 mg/kg/dose	not stated	2/week	4 doses

IDEC 131 (5 mg/kg)

Drug/Treatment	Dose	Route	Frequency	Duration
IDEC 131	5 mg/kg/dose	not stated	2/week	4 doses

IDEC 131 (10 mg/kg)

Drug/Treatment	Dose	Route	Frequency	Duration
IDEC 131	10 mg/kg/dose	not stated	2/week	4 doses

IDEC 131 (15 mg/kg)

Drug/Treatment	Dose	Route	Frequency	Duration
IDEC 131	15 mg/kg/dose	not stated	2/week	4 doses

Results

Multiple doses of IDEC 131 at 1 mg/kg, 5 mg/kg, 10 mg/kg and 15 mg/kg were found to be safe in all patients. Fifteen adverse events were reported of mild to moderate severity which were considered to be possibly treatment-related. IDEC 131 was not associated with any evidence of toxicity as assessed by the Expanded Disability Status Scale, laboratory parameters, relapse rate and other clinical indications.

Adis Assessment

Study Messages

- IDEC 131 at a dosage of 1 mg/kg, 5 mg/kg, 10 mg/kg or 15 mg/kg is generally well tolerated in patients with relapsing-remitting multiple sclerosis.

Adis Evaluation

Trial Design:

Clinical Provides new evidence of clinical benefit and has major implications for a
Relevance: patient population.

Reference

Fadul CE, Ryan KA, Noelle RJ, Wishart HA, Saykin AJ, et al. Therapeutic intervention of multiple sclerosis with a CD40 ligand antagonist: a phase I clinical trial. *Neurology* 60 (Suppl. 1): 84, 11 Mar 2003
Lebanon, New Hampshire, USA

© Adis Data Information BV 2003

Fax Message

To	Dr Stephanie R Amoroso
Company	Darby & Darby
Fax number	00 1 212 753 6237
Matter	European Patent Application No. 99915237.4 Trustees of Dartmouth College
Your ref	20052/2200517-EP4
From	Mr J N Daniels
Our ref	103011/JND/SV
Date	24 March 2005
Number of pages	(Including this one) 7

- ☒ Original will follow by post
- ☐ Original will not follow by post

**Page White
and Farrer**

Patent and
Trade Mark Attorneys

UK
54 Doughty Street
London
WC1N 2LS
Tel +44(0)20 7831 7929
Fax +44(0)20 7831 8040
london@pagewhite.com

Finland
Runeberginkatu 5
10th Floor
FIN-00100 Helsinki
Tel +358 9 343 6510
Fax +358 9 343 6511
helsinki@pagewhite.com

www.pagewhite.com

Directors:
P D Jenkins
Mrs V R Driver
J N Daniels
Ms K C Style
Ms N Shackleton
P R Slingsby
C M Hill
J P Ruuskanen
J P Cornish
D J Williams

Associate Directors:
M N Evans
Miss J H Evenson
Miss C A Wolfe

Mrs A E Campbell

Consultant:
D J Richards

Confidentiality Notice

This fax is intended only for the individual or entity to which it is addressed and may contain confidential or privileged information. If you are not the intended recipient you are hereby notified that any copying, dissemination or distribution of the communication is prohibited. If you have received this communication in error please notify us by telephone or fax and return the original to us at the above address by post.

Registered at the above
London address No. 1319458
and in Finland
No. Y-1749026-1